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INTRODUCTION
The overall therapeutic benefit of an active
pharmaceutical ingredient (API) is dependent
on its potency and efficacy to deliver to the site
of action. Drug delivery systems enable
optimization of the latter by altering the
physicochemical and/or biopharmaceutical
properties of the API(s). Application of nano-
technology for the prevention and the
treatment of diseases has provided a wider
platform for delivery of ‘difficult to deliver’
APIs. This increasing utilization of nano-
technology assisted drug delivery systems
(NADDS) has demonstrated wide-ranging
benefits, from improvement in oral
bioavailability to targeting of drug to specific
tissues.
 
Nano-technology has been defined in a number
of ways. The definition proposed by the
National Nanotechnology Initiative of the US
government encompasses three substantial
points, that is (1) “research and technology
development at the atomic, molecular, or
macromolecular levels, in the length scale of
approximately 1-100 nanometer (nm) range in
any direction”, (2) “creating and using
structures, devices, and systems that have novel
properties and functions as a result of their
small and/or intermediate size” and (3) “ability
to control or manipulate materials on the
atomic or molecular scale” (1).
NADDS exhibit unique properties at the
cellular, atomic and molecular level that are not
present in the bulk material. This not only
allows the alteration of the apparent aqueous
solubility, permeability, bioavailability, potency
and toxicity of the APIs, but can also enable
their targeting to the site of action. These
unique properties can be partially attributed to
the increased surface to volume ratio of such
systems (2). Distinct advantages offered by
nano-technology based products have led to
emergence of numerous drug delivery systems.
On the one hand, there are systems that consist
predominantly of the API (with some
stabilizers) such as nanocrystals and
nanocrystalline in solid dispersions, while on
the other hand there are nano-carrier assisted
drug delivery systems that consist of numerous
ingredients, apart from the API. The latter may
include polymeric nanoparticles, liposomes, self
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nano-emulsifying drug delivery systems, solid
lipid nanoparticles and dendrimers. These
systems have been extensively investigated for
their delivery potential and some of them are
commercially available as enabling technologies.
Marketing approval and commercialization of
pharmaceutical products requires them to pass
through a stringent regulatory review process.
Traditionally, this regulatory pathway has
concentrated on the safety and efficacy of the
medicinal product. However, the contribution
of sub-micron size particles to the unique
properties of NADDSs, requires additional
regulatory scrutiny. There has been a general
lack of regulatory standards for the approval of
NADDSs. As a result, USFDA has taken the
lead in developing a framework for a guidance
document for drug products utilizing nano-
technology. A recent ‘Guidance for Industry”
issued by USFDA in June 2014, has set a two
point agenda for “Considering Whether an
FDA-Regulated Product Involves the
Application of Nano-technology”. For the
purpose of guidance, “nano-technology
products” mean products that contain or are
manufactured using materials in the nano-scale
range, as well as, products that contain or are
manufactured using certain materials that
otherwise exhibit related dimension-dependent
properties or phenomena (3). Hence, apart
from ‘size’, emphasis is also on the products
that demonstrate ‘dimension specific
properties’. The current thinking, rather than
adopting a restrictive view of size, focuses on
“to identify and address potential implications
for safety, effectiveness, public health impact,
or regulatory status of the product”. The
presence of any of the above two criteria would
invite additional scrutiny to identify and address
consequences on safety, effectiveness and
regulatory status.
Role of excipients in NADDSs
 
NADDSs pose unique challenges during their
development and manufacture. Numerous
excipients are used to reach nano-scale size,
prevent aggregation during processing /shelf
life and active targeting to the receptor site and
examples of such excipients are shown in
Table 1.
Table 1 Examples of excipients used in nano-technology






























Many of these excipients have been used
traditionally in other applications and enjoy
GRAS status. However, several others have no
history of being used in previously approved
products through a particular route of
administration. This puts an additional
regulatory burden for the approval of such
products where, apart from the finished
product, the excipient would also attract
regulatory scrutiny.
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Excipients have been traditionally used to
facilitate conversion of APIs into medicinal
products as these are expected to contribute
towards processing, product performance and
stability. Given the diversity of NADDS, such
systems may require a specific three
dimensional structure for their function. Even
the simplest of such systems require excipients
for the generation and maintenance of sub-
micron size particles. Additionally, excipients
may play a crucial role in increasing the
absorption or active targeting. Consequently,
the successful development of NADDSs
requires a thorough understanding of
physicochemical properties and functionality of
the excipients.
Functionality of excipients used in NADDSs
The functionality of an excipient is defined as
the function it performs in a formulation and
the degree to which it meets the intended
function. However, direct testing of
functionality in a formulation or manufacturing
process is not always possible. Therefore, the
European Pharmacopoeia has recently
introduced the concept of ‘Functionality
Related Characteristics’ (FRC) in the non-
mandatory section of the excipient monograph
(4). A FRC is a controllable characteristic of an
excipient that is shown to impact its
functionality. It is now well understood that not
only the API but excipients can alter the
performance of NADDS. Hence, excipients
used in NADDS require unique FRCs to enable
the generation of well defined sub-micron
structures necessary for NADDS.
The concept of FRCs can be explained by
taking the example of stabilizing excipients
used for nanocrystals. Polymers such as PVP
and HPMC are used as steric stabilizers for
nanocrystals. Steric stabilization involves
adsorption of polymer(s) on the surface of API
nanocrystals. This discourages contact between
particles, thus preventing aggregation. The
surface environment of both the polymer(s)
and the nano crystals, influences adsorption
effectivness. Polymer characteristics such as
molecular weight, degree of branching and rate
of hydration can directly influence its role as a
steric stabilizer and could act as FRCs.
However, the FRCs of the same polymer may
change upon alteration in surface environment
of the API nanocrystal. Hence, tailor-made
FRCs could be required for excipients used in
NADDS, as functionality can only be tested in
the context of a particular formulation and its
manufacturing process. This would be much
more complex for multi-component three
dimensional constructs, and would require a
detailed orthogonal testing for identification of
FRCs.
Nano-excipients
Nano-excipients are excipients existing in
nanometer size range. These might be
manufactured deliberately or generated
unintentionally during manufacturing of
NADDS. The process of manufacturing
NADDS can have the potential of converting
an excipient into its “nano” form. The
existence of nano-excipients in finished drug
products was recently highlighted by Moreton.
This can alter the properties of the excipient,
thereby enhancing its transport across
biological membranes (5). Therefore, it is
expected that nano-excipients would require
additional safety evaluation in comparison to
the non-nano excipients.
Nano-excipients and regulatory expectations
The thought process of USFDA in assessing
nano-excipients is shown in the recently issued
guidance document entitled “Assessing the
effects of significant manufacturing process
changes, including emerging technologies, on
the safety and regulatory status of food
ingredients and food contact substances,
including food ingredients that are color
additives”(6). This document touches upon the
use of nano-technology in food substances.
While ignoring the presence of nano-range
particles in existing substances, the focus is on
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an intentional alteration of particles to
nanometer scale. Though a closer assessment of
such products has been recommended, the final
assessment of safety is to be based on the
characteristics of the finished product and the
safety of its intended use. However, it must be
stressed that the yardstick applied to
conventionally manufactured food substances
cannot be blindly extrapolated to nano-
engineered food substances.
This guidance document has also questioned
the applicability of traditional safety tests of
nano-engineered food substances. The need for
developing validated in vitro toxicity assays for
nano-engineered food substances has been
stressed. This will enable meaningful safety
assessment of nano-engineered food
substances. It is reasonable to conclude that a
similar philosophy should be adopted for nano-
engineered pharmaceutical excipients.
CONCLUSION
Much research has been carried out on
NADDS. Commercialization of these
technologies would depend on how well they
meet the criteria for safety and efficacy. In
particular, upfront consideration of regulatory
expectations not only from the delivery system
but also the excipients, would ensure higher
success rates. Looking forward nano-
technology enabling excipients will witness
intensive scientific investigations, as they have
the capacity to contribute unique functionality
to the drug products.
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